Adell Harriman & Carpenter Inc. Buys Shares of 999 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Adell Harriman & Carpenter Inc. acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 999 shares of the company's stock, valued at approximately $413,000.

Other large investors have also made changes to their positions in the company. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after buying an additional 60 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Up 0.4 %

NASDAQ:IDXX traded up $1.93 during mid-day trading on Wednesday, hitting $450.99. The company had a trading volume of 578,701 shares, compared to its average volume of 707,372. The business has a fifty day simple moving average of $430.91 and a 200-day simple moving average of $452.43. The firm has a market capitalization of $36.93 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 3.35 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,330 shares of company stock worth $6,161,276. 2.18% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IDXX shares. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective for the company. Finally, Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.